Skip to main content

Advertisement

SpringerLink
Log in

IL28B rs12980275 and HLA rs4273729 genotypes as a powerful predictor factor for rapid, early, and sustained virologic response in patients with chronic hepatitis C

  • Original Article
  • Published:
Archives of Virology Aims and scope Submit manuscript

Abstract

Single-nucleotide polymorphisms (SNPs) in the Interleukin-28B (IL28B) gene and rs4273729 in the human leukocyte antigen (HLA) gene in chronic hepatitis C (CHC) virus infection are important for predicting treatment outcome. In this study, the distribution of IL28B SNPs (rs12979860 and rs12980275) and HLA rs4273729 in rapid virologic response (RVR), complete early virologic response (cEVR) and sustained virologic response (SVR) in HCV Iranian patients with CHC virus infection was assessed. IL28B genotyping and rs4273729 were performed using the amplification refractory mutation system (ARMS)-PCR and direct sequencing in 190 CHC virus infections, respectively. RVR, cEVR, and SVR were 53.2 %, 78.9 %, and 65.8 %, respectively. Multivariate regression analysis demonstrated that the responses significantly predicted SVR in patients with age <40 years (p = 0.008), HCV genotypes (p = 0.032), IL28B rs12979860 CC genotype (p < 0.001), rs12980275 AA genotype (p < 0.001), rs4273729 GG genotype (p < 0.001), RVR (p < 0.001) and cEVR (p = 0.024). Three critical predictor factors based on RVR response were rs12979860 CC genotype (p = 0.033), rs12980275 AA genotype (p < 0.001) and rs4273729 GG genotype (p < 0.001), while rs12980275 AA (p = 0.003) and rs4273729 GG genotypes (p < 0.001) predicted cEVR. For the first time in Iran, these results revealed that the rs12980275 and HLA rs4273729 are important for the treatment of CHC infection. These findings may help predict responses to CHC infection treatment and reduce the cost and side effects of therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Afdhal NH, McHutchison JG, Zeuzem S, Mangia A, Pawlotsky JM, Murray JS, Shianna KV, Tanaka Y, Thomas DL, Booth DR (2011) Hepatitis C pharmacogenetics: state of the art in 2010. Hepatol 53:336–345

    Article  Google Scholar 

  2. Aziz H, Raza A, Ali K, Khattak JZK, Irfan J, Gill ML (2015) Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy. Int J Infect Dis 30:91–97

    Article  CAS  PubMed  Google Scholar 

  3. Covolo L, Bibert S, Donato F, Bochud PY, Lagging M, Negro F, Fattovich G (2014) The novel ss469415590 variant predicts virological response to therapy in patients with chronic hepatitis C virus type 1 infection. Aliment Pharmacol Ther 39:322–330

    Article  CAS  PubMed  Google Scholar 

  4. Dong ZX, Zhou HJ, Xiang XG, Guo SM, Zhuang Y, Zhao GD, Xie Q (2015) IL28B genetic variations are associated with treatment response of patients with chronic hepatitis C in a Chinese Han population. J Dig Dis 16:90–97

    Article  CAS  PubMed  Google Scholar 

  5. Duggal P, Thio CL, Wojcik GL, Goedert JJ, Mangia A, Latanich R, Kim AY, Lauer GM, Chung RT, Peters MG, Kirk GD, Mehta SH, Cox AL, Khakoo SI, Alric L, Cramp ME, Donfield SM, Edlin BR, Tobler LH, Busch MP, Alexander G, Rosen HR, Gao X, Abdel-Hamid M, Apps R, Carrington M, Thomas DL (2013) Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med 158:235–245

    Article  PubMed  PubMed Central  Google Scholar 

  6. Fateh A, Aghasadeghi M, Keyvani H, Mollaie H, Yari S, Hadizade TA, Ghazanfari M, Monavari S (2015) High Resolution Melting Curve Assay for Detecting rs12979860 IL28B Polymorphisms Involved in Response of Iranian Patients to Chronic Hepatitis C Treatment. Asian Pac J Cancer Prev 16:1873–1880

    Article  PubMed  Google Scholar 

  7. Fateh A, Aghasadeghi M, Siadat SD, Vaziri F, Sadeghi F, Fateh R, Keyvani H, Tasbiti AH, Yari S, Ataei-Pirkooh A (2016) Comparison of three different methods for the detection of IL28 rs12979860 polymorphisms as treatment predictor factor for the hepatitis C virus. Osong Public Health and Research Perspectives. Osong Public Health Res Perspect. 7:83–89

    Article  PubMed  Google Scholar 

  8. Fathy MM, Taleb MEA, El Hawary MS, Nabih MI, Aref WM, Makhlouf MM (2015) Assessment of interleukin 28B genotype as a predictor of response to combined therapy with pegylated interferon plus ribavirin in HCV infected Egyptian patients. Cytokine 74:268–272

    Article  CAS  PubMed  Google Scholar 

  9. Ferenci P, Laferl H, Scherzer TM, Gschwantler M, Maieron A, Brunner H, Stauber R, Bischof M, Bauer B, Datz C (2008) Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 135:451–458

    Article  CAS  PubMed  Google Scholar 

  10. Franco S, Tural C, Clotet B, Martinez MA (2012) Alleles at rs4273729 in the chromosome 6 do not predict response to peg-interferon-α and ribavirin therapy in hepatitis C virus/HIV-1—coinfected patients. AIDS 26:1973–1974

    Article  PubMed  Google Scholar 

  11. Ghany MG, Strader DB, Thomas DL, Seeff LB (2009) Diagnosis, management, and treatment of hepatitis C: an update. Hepatol 49:1335–1374

    Article  CAS  Google Scholar 

  12. Golden-Mason L, Klarquist J, Wahed A, Rosen H (2008) PD-1 expressin is increased on immunocytes in chronic HCV and predicts failure of response to antiviral therapy, race-dependent differences. J Immunol. 180:3637–3641

    Article  CAS  PubMed  Google Scholar 

  13. Imran M, Manzoor S, Azam S, Resham S (2015) Genetic variant of IL28B rs12979860, as predictive marker of interferon-based therapy in Pakistani population. APMIS 123:342–349

    Article  CAS  PubMed  Google Scholar 

  14. Khubaib B, Saleem S, Idrees M, Afzal S, Wasim M (2015) The genotype CC of IL-28B SNP rs12979860 is significantly associated with a sustained virological response in chronic HCV-infected Pakistani patients. J Dig Dis 16:293–298

    Article  CAS  PubMed  Google Scholar 

  15. Ling Q, Chen J, Zhou H, Zhong J, Chen Y, Ye Q, Zhuo Y, Min N, Shang B (2015) Baseline factors associated with treatment response in patients infected with hepatitis C virus 1b by stratification of IL28B polymorphisms. Arch Virol 160:1105–1112

    Article  CAS  PubMed  Google Scholar 

  16. European Association for The Study of The Liver (2014) EASL recommendations on treatment of hepatitis C 2014. J Hepatol 61:373–395

    Article  Google Scholar 

  17. Namazee N, Sali S, Asadi S, Shafiei M, Behnava B, Alavian SM (2012) Real response to therapy in chronic hepatitis C virus patients: a study from iran. Hepat Mon 12:e6151

    Article  PubMed  PubMed Central  Google Scholar 

  18. World Health Organization (2014) Guidelines for the screening, care and treatment of persons with hepatitis C infection. http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/. Accessed April 2014

  19. Resham S, Manzoor S, Imran M, Saalim M, Naseem S, Azam S (2015) Interleukin-28B: a prognostic marker in interferon based therapy of chronic HCV patients of the Pakistan with variable treatment response. APMIS 123:765–771

    Article  CAS  PubMed  Google Scholar 

  20. Rosen HR, Weston SJ, Im K, Yang H, Burton JR Jr, Erlich H, Klarquist J, Belle SH (2007) Selective decrease in hepatitis C virus-specific immunity among African Americans and outcome of antiviral therapy. Hepatol 46:350–358

    Article  CAS  Google Scholar 

  21. Sarrazin C, Susser S, Doehring A, Lange CM, Müller T, Schlecker C, Herrmann E, Lötsch J, Berg T (2011) Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol 54:415–421

    Article  CAS  PubMed  Google Scholar 

  22. Scherzer T-M, Hofer H, Staettermayer AF, Rutter K, Beinhardt S, Steindl-Munda P, Kerschner H, Kessler HH, Ferenci P (2011) Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin. J Hepatol 54:866–871

    Article  CAS  PubMed  Google Scholar 

  23. Shaikh N, Waryah AM, Devrajani BR, Rajput MI, Hayat AS, Shaikh S (2015) IL28B rs12980275 polymorphism shows association with response to treatment in Pakistani patients with Chronic Hepatitis C. J Med Virol 87:814–820

    Article  CAS  PubMed  Google Scholar 

  24. Sixtos-Alonso MS, Avalos-Martinez R, Sandoval-Salas R, Dehesa-Violante M, García-Juarez I, Chávez-Ayala A, Domínguez-López A, Vargas-Vorácková F, Toapanta-Yanchapaxi L, Amezcua-Guerra LM (2015) A genetic variant in the interleukin 28B gene as a major predictor for sustained virologic response in chronic hepatitis C virus infection. Arch Med Res 46:448–453

    Article  CAS  PubMed  Google Scholar 

  25. Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, Simmonds P (2014) Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatol 59:318–327

    Article  Google Scholar 

  26. Taherkhani R, Farshadpour F (2015) Epidemiology of hepatitis C virus in Iran. World J Gastroenterol 21:10790–10810

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O’hUigin C, Kidd J, Kidd K, Khakoo SI, Alexander G (2009) Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461:798–801

  28. Xu Y, Huang P, Yue M, Su J, Chen H, Chen M, Wang J, Li J, Peng Z, Zhang Y, Yu R (2016) A novel polymorphism near HLA class II region is associated with spontaneous clearance of HCV and response to interferon treatment in Chinese patients. J Hum Genet 61:301–305

    Article  CAS  PubMed  Google Scholar 

  29. Yu JW, Wang GQ, Sun LJ, Li XG, Li SC (2007) Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon α-2a and ribavirin. J Gastroenterol Hepatol 22:832–836

    Article  CAS  PubMed  Google Scholar 

  30. Zhang L, Jilg N, Shao R-X, Lin W, Fusco DN, Zhao H, Goto K, Peng LF, Chen W-C, Chung RT (2011) IL28B inhibits hepatitis C virus replication through the JAK–STAT pathway. J Hepatol 55:289–298

    Article  CAS  PubMed  Google Scholar 

  31. Zhang XH, Cai QX, Hong CX, Lin CS, Zhao ZX (2013) Prevalence of IL-28B and ITPA genotypes in Chinese Han population infected persistently with hepatitis C virus genotype 6 or HCV-1. J Med Virol 85:1163–1169

    Article  CAS  PubMed  Google Scholar 

  32. Zheng H, Li M, Chi B, Wu XX, Wang J, Liu DW (2015) IL28B rs12980275 variant as a predictor of sustained virologic response to pegylated-interferon and ribavirin in chronic hepatitis C patients: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 39:576–583

    Article  CAS  PubMed  Google Scholar 

  33. Domagalski K, Pawlowska M, Tretyn A, Halota W, Tyczyno M, Kozielewicz D, Dybowska D (2013) Association of IL28B polymorphisms with the response to Peginterferon plus ribavirin combined therapy in polish patients infected with HCV genotype 1 and 4. Hepat Mon 13:e13678

    Article  PubMed  PubMed Central  Google Scholar 

  34. Boyum A (1968) Separation of leukocytes from blood and bone marrow. Introduction. Scand J Clin Lab Invest Suppl. 97:7

    CAS  PubMed  Google Scholar 

Download references

Acknowledgment

We would like to thank all of the patients who participated in the study. We are particularly grateful to Naser Kalhor for their valuable comments and sharing their knowledge.

Author information

Authors and Affiliations

  1. Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran

    Parvaneh Sedighimehr & Shiva Irani

  2. Departments of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran

    Fatemeh Sakhaee, Farzam Vaziri, Fatemeh Rahimi Jamnani, Abolfazl Fateh & Seyed Davar Siadat

  3. Microbiology Research Center (MRC), Pasteur Institute of Iran, Tehran, Iran

    Farzam Vaziri, Fatemeh Rahimi Jamnani, Abolfazl Fateh & Seyed Davar Siadat

  4. Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran

    Mohammadreza Aghasadeghi & Seyed Mehdi Sadat

Authors
  1. Parvaneh Sedighimehr
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shiva Irani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fatemeh Sakhaee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Farzam Vaziri
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mohammadreza Aghasadeghi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Seyed Mehdi Sadat
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Fatemeh Rahimi Jamnani
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Abolfazl Fateh
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Seyed Davar Siadat
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Abolfazl Fateh.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sedighimehr, P., Irani, S., Sakhaee, F. et al. IL28B rs12980275 and HLA rs4273729 genotypes as a powerful predictor factor for rapid, early, and sustained virologic response in patients with chronic hepatitis C. Arch Virol 162, 181–189 (2017). https://doi.org/10.1007/s00705-016-3095-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00705-016-3095-1

Keywords

Search

Navigation